MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0

MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Amendment to 2015 Stock Incentive Plan

On March2, 2017, the Board of Directors of Madrigal Pharmaceuticals,Inc. (the “Company”) approved, subject to stockholder approval, an amendment to the Company’s 2015 Stock Plan (as amended, the “Plan”), which was approved by the Company’s stockholders at the 2017 annual meeting of stockholders held on June29, 2017 (the “Annual Meeting”). The Plan amendment increased the total number of shares of common stock reserved for issuance under the Plan by 1,000,000 shares and increased the amount of awards that a participant will be entitled to receive in any fiscal year from 571,429 shares of common stock to 750,000 shares of common stock.

The foregoing description of the Plan amendment does not purport to be complete and is qualified in its entirety by reference to the Plan, a copy of which is attached as Exhibit10.1 to this Current Report on Form8-K (this “Current Report”) and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held the Annual Meeting on Thursday, June29, 2017 at the Philadelphia Marriott West, 111 Crawford Avenue, Conshohocken, Pennsylvania 19428. As of May1, 2017, the record date for the Annual Meeting, the Company had 12,167,405 shares of its common stock outstanding and entitled to vote, of which 11,156,261 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote at the Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting.

Proposal No.1: The Company’s stockholders elected each of the two ClassI nominees named below to serve on the Company’s Board of Directors for a three-year term expiring at the Company’s 2020 annual meeting of stockholders and until their respective successors are duly elected and qualified.

ClassINominee

VotesFor

VotesWithheld

BrokerNon-votes

Paul A. Friedman, M.D.

9,166,195

11,869

1,978,197

Kenneth M. Bate

9,075,444

102,620

1,978,197

Proposal No.2: The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2017.

VotesFor

VotesAgainst

VotesAbstaining

BrokerNon-Votes

11,084,506

62,374

9,381

Proposal No.3: The Company’s stockholders approved an amendment to the Plan increasing the aggregate number of shares authorized for issuance thereunder by 1,000,000 shares of common stock and increasing the amount of awards that a participant will be entitled to receive thereunder in any fiscal year from 571,429 shares of common stock to 750,000 shares of common stock.

VotesFor

VotesAgainst

VotesAbstaining

BrokerNon-Votes

9,028,105

143,575

6,384

1,978,197

Proposal No.4: The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as described in the proxy statement for the Annual Meeting.

VotesFor

VotesAgainst

VotesAbstaining

BrokerNon-Votes

9,119,966

49,083

9,015

1,978,197

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are attached to this Current Report on Form8-K:

ExhibitNo.

Description

10.1

2015 Stock Plan, as amended


MADRIGAL PHARMACEUTICALS, INC. Exhibit
EX-10.1 2 a2232615zex-10_1.htm EX-10.1 QuickLinks — Click here to rapidly navigate through this document Exhibit 10.1 MADRIGAL PHARMACEUTICALS,…
To view the full exhibit click here

About MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL) Recent Trading Information

MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL) closed its last trading session 00.00 at 16.26 with 7,000 shares trading hands.